Dr. Coleman, a member of the Alliance’s Scientific and Medical Advisory Board, conducted an interview on ovarian cancer therapies for the Cancer Network. He discussed the heterogeneity of ovarian cancer, angiogenesis inhibitors and new drugs in the pipeline.

The full interview can be found here